(Q34571800)

3 August 2017

1 reference

title

STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia (English)

1 reference

3 August 2017

1 reference

1 reference

M E O'Dwyer

1

1 reference

3 August 2017

B J Druker

series ordinal

2

1 reference

3 August 2017

language of work or name

1 reference

1 December 2000

1 reference

Lancet Oncology Commission

3 August 2017

published in

1 reference

3 August 2017

volume

1

1 reference

3 August 2017

page(s)

207-211

1 reference

3 August 2017

cites work

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Structural organization of the bcr gene and its role in the Ph' translocation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

A transformation-defective mutant of Abelson murine leukemia virus lacks protein kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Acute leukaemia in bcr/abl transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Biology of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900149-2

7 January 2021

10.1016/S1470-2045(00)00149-2

Identifiers

DOI

1 reference

3 August 2017

1 reference